Patent intelligence · US
US 11648232
Methods and compositions for treating excessive sleepiness
Methods and compositions for treating excessive sleepiness
Patent details — US 11648232
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 16, 2023
- Expiration
- May 11, 2043
- Applicant
- AXSOME MALTA LTD.
- Claims
- 16
- CPC classes
- A61K, A61K31/27, A61K9/0053, A61K9/20
Quick answer
US 11648232 (Methods and compositions for treating excessive sleepiness) is held by AXSOME MALTA LTD.. Status: granted. Granted May 16, 2023. Expires May 11, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AXSOME MALTA LTD.
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K31/27, A61K9/0053, A61K9/20, A61K9/2054, A61K9/48
More from AXSOME MALTA LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12390419
Formulations of (R)-2-amino-3-phenylpropyl carbamate
granted -
US 12384743
Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof
granted -
US 12370196
Pharmaceutical compositions comprising meloxicam
granted -
US 12357640
Pharmaceutical compositions comprising meloxicam
granted -
US 12357697
Pharmaceutical compositions comprising bupropion and cysteine
granted -
US 12318362
Methods of providing solriamfetol therapy to subjects with impaired renal function
granted -
US 12268693
Pharmaceutical compositions comprising a tolfenamic acid
granted -
US 12263145
Methods of administering solriamfetol to lactating women
granted
Frequently asked questions
What is US patent 11648232?
US 11648232 (Methods and compositions for treating excessive sleepiness) is held by AXSOME MALTA LTD.. Status: granted. Granted May 16, 2023. Expires May 11, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11648232?
AXSOME MALTA LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 162 pharmaceutical patents for this assignee.
When does US 11648232 expire?
Our index shows an expiration date of May 11, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.